ARTICLE | Clinical News
ACE-031 regulatory update
August 9, 2010 7:00 AM UTC
FDA granted Fast Track designation for Acceleron's ACE-031 to treat Duchenne muscular dystrophy (DMD). The myostatin (GDF8) inhibitor is currently in Phase II testing for the indication. ...